Pfizer’s CEO Sold $5.6 Million In Stock On Vaccine News Day

Pfizer CEO Albert Bourla filed to sell millions of dollars of his company’s stock Monday — the day the pharmaceutical giant announced positive data about its coronavirus vaccine.

The company’s shares soared after Pfizer and European drug company BioNTech said early data suggests the vaccine could be more than 90% effective.

The transaction was part of a regularly scheduled plan set up by Bourla to periodically sell some of his Pfizer shares.

The Numbers

Bourla sold 132,508 Pfizer (PFE) shares at a price of $41.94, according to a filing with the Securities and Exchange Commission. That works out to proceeds of nearly $5.6 million.

A Pfizer spokeswoman said in an that the sale took place because Pfizer shares hit a predetermined price as part of a plan authorized by Bourla on August 19.

Why Sell?

When asked if Pfizer and Bourla thought to cancel the stock sale due to the perception that Bourla might be cashing in on good news, the spokeswoman said that “these are predetermined plans managed through a third-party stock administrator.”

Another Pfizer officer, executive vice president Sally Susman, also sold shares Monday as part of a prearranged plan. Susman sold 43,662 shares at the same $41.94 price that Bourla sold at, a transaction valued at more than $1.8 million.

Many executives sell stock at predetermined intervals to diversify their portfolios. But they can delay the sales to avoid appearances of capitalizing on one-off events that can boost company’s shares.

Bouria told Sanjay Gupta that he learned of the trial’s results Sunday, a day before they were made public.

The Moderna Vaccine Story

Shares of Pfizer surged nearly 8% Monday and were flat Tuesday. BioNTech’s (BNTX)stock has rallied even more sharply, rising 15% Monday and another 8% Tuesday. Pfizer’s stock fell more than 1% Wednesday.

The Pfizer stock sale comes just a few months after executives at Moderna (MRNA), a biotech also working on a Covid-19 vaccine, sold shares following the release of promising trial results.

Critics accused Moderna of overhyping the vaccine trial results, but the company nonetheless raised $1.3 billion in a stock sale immediately following the vaccine trial announcement.

Executives then sold tens of millions of dollars worth of Moderna shares before the company’s stock price fizzled a week later.

Some former SEC officials called on Moderna to be investigated for potential illegal market manipulation.

Clout News

Recent Posts

FaZe Clan Announces 21-Year-Old Twitch streamer Lacy As Newest Member

Lacy is a 21-year-old Twitch streamer who is famous for playing Fortnite and has a…

1 day ago

READ: Tristan Tate Reveals His Earnings from X Ad Revenue Share Program

Let us see how much contribution does X make to Tristan Tate's net worth. You…

1 day ago

Jake Paul Vs Mike Tyson: Fight Date, Time, How to watch, and more

Jake Paul vs Mike Tyson fight is happening on Saturday, July 20, 2024 at the…

2 days ago

Why did Streaming Company Paramount’s CEO Bob Bakish Step Down?

According to various news outlets, this has to do with the upcoming merger deal of…

2 days ago

Morreale Paris Unveils New Fragrance Collection with Mesmerizing Film Campaign “The Party”

In a dazzling display of elegance and youthful exuberance, Morreale Paris has introduced its latest…

2 weeks ago

Jason Jouan’s Phenomenal Journey to Real Estate Success

Jason's journey is like a business adventure. He's not just building properties; he's building a…

4 months ago